Equities research analysts at StockNews.com started coverage on shares of Retractable Technologies (NYSE:RVP – Get Free Report) in a report released on Friday. The firm set a “hold” rating on the stock.
Retractable Technologies Trading Up 1.0 %
NYSE RVP opened at $0.64 on Friday. The firm has a market capitalization of $19.04 million, a PE ratio of -1.18 and a beta of 1.98. The business’s 50-day moving average price is $0.69 and its two-hundred day moving average price is $0.90. The company has a current ratio of 8.57, a quick ratio of 5.92 and a debt-to-equity ratio of 0.01. Retractable Technologies has a 12 month low of $0.56 and a 12 month high of $1.34.
Insider Buying and Selling at Retractable Technologies
In other news, CEO Thomas J. Shaw purchased 71,422 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were purchased at an average price of $0.82 per share, for a total transaction of $58,566.04. Following the transaction, the chief executive officer now owns 14,743,907 shares of the company’s stock, valued at approximately $12,090,003.74. This trade represents a 0.49 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders bought 176,995 shares of company stock valued at $132,936. 55.00% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Retractable Technologies
Retractable Technologies Company Profile
Retractable Technologies, Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes.
Featured Stories
- Five stocks we like better than Retractable Technologies
- The Risks of Owning Bonds
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Dividend Payout Ratio Calculator
- Texas Instruments: The Old-School Tech Titan Still Delivering
- What is Short Interest? How to Use It
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Retractable Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retractable Technologies and related companies with MarketBeat.com's FREE daily email newsletter.